Articles

Back to Articles

Pregabalin Sets the Standard for Effectual, Quick and Tolerable Pain Relief

(Pub. 13th August, 2012)

Patients suffering from fibromyalgia, diabetic nerve pain, and pain caused by shingles will find optimum pain relief from Pregabalin.  As the only medication that is FDA approved for both the management of diabetic peripheral neuropathy and post herpetic neuralgia, Pregabalin may also be used to treat partial onset seizures in adults with epilepsy who take one or more drugs for seizures. What makes Pregabalin unique is that it has a high bioavailability and is rapidly absorbed in the body, thus requiring a lower dosage to be effectual. When compared to Gabapentin, a medication commonly prescribed to treat neuropathic pain, Pregabalin proves to be equally as effective for pain management, but with a much lower dosage required to be efficacious. While Gabapentin is slowly absorbed in the body, with a peak at 3 to 4 hours post-dose, Pregabalin is rapidly absorbed with a peak at 1 hour post-dose. In addition, plasma concentrations of Gabapentin have a non-linear relationship to increasing doses, whereas plasma concentrations increase linearly with higher dosages of Pregabalin.  This provides a distinct pharmacokinetic advantage for Pregabalin when compared to Gabapentin.

Pregabalin is also known as the brand name Lyrica, which entered the pharmaceutical market in December of 2004. The greatest advantage for prescribers of Pregabalin is the ability for them to prescribe the lowest dose possible of this medication while still retaining optimal pain relief for patients. Another advantage of Pregabalin, versus Gabapentin, is that physicians can offer neuropathic pain relief for patients with a starting dose of 50-75 milligrams, twice daily of Pregabalin, compared to an 1800 milligram daily dose of Gabapentin. The higher dose required to relieve pain when using Gabapentin causes adverse side effects like extreme drowsiness and an overwhelming sensation of confusion and disequilibrium for patients. Many physicians choose to slowly up the dosage of Gabapentin for patients to possibly alleviate some of these life altering side effects. In comparison, Pregabalin can be absorbed more efficiently and easily by patients, thus allowing for a speedier increase of this drug if it is needed,  but without the “drugged” sensation that patients taking Gabapentin report.

On June 21, 2012 Pfizer, the makers of Lyrica received an added approval for the use of Pregabalin, specifically as a treatment for nerve pain associated with spinal cord injuries. This news sent the price of Pfizer’s stocks up 14 cents, or 0.6 percent. Sales of Lyrica (Pregabalin) in the first quarter of 2012 reached an astounding 395 million dollars, making it the second best-selling drug for Pfizer. With continued research and development for novel ways that Pregabalin can be utilized for pain relief, this medication has the potential for a variety of uses in the near future. The safety, bioavailability, tolerability and prior success all add up to a profitable future for Pregabalin.

YES Pharma is proud to be a leading supply source for Pregabalin (CAS# : 148553-50-8) to several global pharmaceutical companies and academic research institutes, while recognizing that we play a significant part in promoting the struggle against  fibromyalgia, diabetic nerve pain, and pain caused by shingles. The Pregabalin that YES Pharma supplies is intended for laboratory R&D use only.

 

References:

Drugs Publication, “Pregabalin: in the treatment of postherpetic neuralgia
Drug Development- Technology.com

  • Products covered by valid patents are not offered or supplied for commercial use.
  • Products currently covered by valid US patents are offered only for laboratory R&D use in accordance with 35 USC 271(e)+A13(1).                
  • Any patent infringement and resulting liability is solely at buyer risk

 

Dun and Bradstreet